首页> 美国卫生研究院文献>Diabetes >Noninvasive In Vivo Imaging of Diabetes-Induced Renal Oxidative Stress and Response to Therapy Using Hyperpolarized 13C Dehydroascorbate Magnetic Resonance
【2h】

Noninvasive In Vivo Imaging of Diabetes-Induced Renal Oxidative Stress and Response to Therapy Using Hyperpolarized 13C Dehydroascorbate Magnetic Resonance

机译:使用超极化13C脱氢抗坏血酸磁共振对糖尿病引起的肾脏氧化应激的非侵入性体内成像和对治疗的反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oxidative stress has been proposed to be a unifying cause for diabetic nephropathy and a target for novel therapies. Here we apply a new endogenous reduction-oxidation (redox) sensor, hyperpolarized (HP) 13C dehydroascorbate (DHA), in conjunction with MRI to noninvasively interrogate the renal redox capacity in a mouse diabetes model. The diabetic mice demonstrate an early decrease in renal redox capacity, as shown by the lower in vivo HP 13C DHA reduction to the antioxidant vitamin C (VitC), prior to histological evidence of nephropathy. This correlates with lower tissue reduced glutathione (GSH) concentration and higher NADPH oxidase 4 (Nox4) expression, consistent with increased superoxide generation and oxidative stress. ACE inhibition restores the HP 13C DHA reduction to VitC with concomitant normalization of GSH concentration and Nox4 expression in diabetic mice. HP 13C DHA enables rapid in vivo assessment of altered redox capacity in diabetic renal injury and after successful treatment.
机译:已经提出氧化应激是糖尿病性肾病的统一原因和新疗法的靶标。在这里,我们将一种新型内源性还原-氧化(redox)传感器,超极化(HP) 13 C脱氢抗坏血酸(DHA)与MRI结合使用,以无创方式询问小鼠糖尿病模型中的肾脏氧化还原能力。糖尿病小鼠表现出早期的肾脏氧化还原能力降低,这是在肾脏病的组织学证据之前,体内HP 13 C DHA降低为抗氧化剂维生素C(VitC)的程度较低。这与较低的组织减少的谷胱甘肽(GSH)浓度和较高的NADPH氧化酶4(Nox4)表达相关,这与增加的超氧化物生成和氧化应激相一致。 ACE抑制可将糖尿病小鼠的GSH浓度和Nox4表达正常化,从而将HP 13 C DHA还原为VitC。 HP 13 C DHA可以快速体内评估糖尿病性肾损伤和成功治疗后氧化还原能力的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号